Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Hosing

Showing results (121-130 of 234) with videos related to

Pageof 24
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.
British Journal of Haematology|January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantationFleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Blood|December 22, 2005
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHDDaniel R Couriel, Chitra Hosing, Rima Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2018
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell TransplantationAimaz Afrough, Rima M Saliba, Amir Hamdi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory LymphomaYago Nieto, Jeremy Ramdial, Benigno Valdez, et al.
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
Journal of Blood Medicine|January 28, 2012
A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomasChitra Hosing, Mark F Munsell, James M Reuben, et al.
Transplantation and Cellular Therapy|December 2, 2023
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin LymphomaYago Nieto, Pinaki Banerjee, Indresh Kaur, et al.
The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.
Leukemia & Lymphoma|July 26, 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myelomaQaiser Bashir, Nina Shah, Simrit Parmar, et al.
Pageof 24

Showing results (121-130 of 234) with videos related to

Sort By:
Pageof 24
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2014
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantationYi Zhou, Rebecca Slack, Jeffrey L Jorgensen, et al.
British Journal of Haematology|January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantationFleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Blood|December 22, 2005
Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHDDaniel R Couriel, Chitra Hosing, Rima Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2018
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell TransplantationAimaz Afrough, Rima M Saliba, Amir Hamdi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2025
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory LymphomaYago Nieto, Jeremy Ramdial, Benigno Valdez, et al.
Leukemia & Lymphoma|July 24, 2018
High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomesBei Hu, Peter Thall, Denái R Milton, et al.
Journal of Blood Medicine|January 28, 2012
A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomasChitra Hosing, Mark F Munsell, James M Reuben, et al.
Transplantation and Cellular Therapy|December 2, 2023
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin LymphomaYago Nieto, Pinaki Banerjee, Indresh Kaur, et al.
The Lancet. Haematology|July 27, 2024
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 studyAlex F Herrera, Jasmine Zain, Kerry J Savage, et al.
Leukemia & Lymphoma|July 26, 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myelomaQaiser Bashir, Nina Shah, Simrit Parmar, et al.
Pageof 24